LoginGet started
Picture of Genor Biopharma Holdings logo

6998 — Genor Biopharma Holdings Income Statement

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock
Balance sheetIncome statementCashflow
Subscribe to view all data

Annual income statement for Genor Biopharma Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSARSARSARSPRESS
Standards:
IFRS
IFRS
IFRS
IFRS		—
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue1310.3015.90
Cost of Revenue
Gross Profit3.487.74014.90
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses5342,913859799711
Operating Profit-521-2,903-859-783-711
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-524-3,036-866-732-677
Provision for Income Taxes
Net Income After Taxes-523-3,031-865-730-675
Minority Interest
Net Income Before Extraordinary Items
Net Income-522-3,027-865-730-674
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-522-3,027-865-730-674
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.45-12.2-1.75-1.45-1.18